BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:23 PM
 | 
Mar 06, 2007
 |  BC Extra  |  Clinical News

Faropenem meets otitis media endpoint

Replidyne (RDYN) said faropenem was effective in eradicating pathogens from the middle ear in a Phase II trial to treat pediatric otitis media. The dose-ranging trial enrolled more than 300 pediatric patients...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >